Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha-Pipeline Review H2 2017
ReportsWeb.com has announced the addition of the “Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha-Pipeline Review H2 2017” this report provides an overview of the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Al
(EMAILWIRE.COM, July 26, 2017 ) According to the recently published report 'Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha-Pipeline Review H2 2017'; Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)-Granulocyte macrophage colony stimulating factor receptor subunit alpha also known as CD116 is a receptor for granulocyte macrophage colony-stimulating factor. It is a member of the cytokine family of receptors. It plays an important role in controls the production differentiation and function of granulocytes and macrophages.
The report 'Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha-Pipeline Review H2 2017' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently The molecules developed by companies in Phase III Phase II Phase I and Preclinical stages are 2 4 1 and 3 respectively. Similarly the universities portfolio in Preclinical stages comprises 1 molecules respectively. Report covers products from therapy areas Oncology Respiratory Toxicology Central Nervous System Dermatology Gastrointestinal and Infectious Disease which include indications Prostate Cancer Colorectal Cancer Lung Disease Melanoma Radiation Toxicity (Radiation Sickness Acute Radiation Syndrome) Acute Respiratory Distress Syndrome Alzheimer's Disease Appendicitis Asthma Chemotherapy Induced Neutropenia Chronic Obstructive Pulmonary Disease (COPD) Crohn's Disease (Regional Enteritis) Lung Infections Lung Injury Malignant Pleural Mesothelioma Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Mild Cognitive Impairment Neurology Ovarian Cancer Parkinson's Disease Peritonitis Radiation Induced Myelosuppression Radiation Injury Respiratory Syncytial Virus (RSV) Infections Skin Ulcers and Wounds.
For more information about this report at http://www.reportsweb.com/granulocyte-macrophage-colony-stimulating-factor-receptor-subunit-alpha-pipeline-review-h2-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
- The report reviews Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
- The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881476/sample
Reasons to buy
- Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Aduro BioTech Inc
Bolder Biotechnology Inc
Genzyme Corp
Johnson & Johnson
OncBioMune Pharmaceuticals Inc
Pharmaxis Ltd
Savara Inc
Targovax ASA
XL-protein GmbH
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881476/discount
List of Tables
Number of Products under Development by Stage of Development H2 2017
Number of Products under Development by Therapy Areas H2 2017
Number of Products under Development by Indications H2 2017
Number of Products under Development by Indications H2 2017 (Contd..1) H2 2017
Number of Products under Development by Companies H2 2017
Products under Development by Companies H2 2017
Products under Development by Companies H2 2017 (Contd..1) H2 2017
Number of Products under Investigation by Universities/Institutes H2 2017
Products under Investigation by Universities/Institutes H2 2017
Number of Products by Stage and Mechanism of Actions H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Pipeline by Aduro BioTech Inc H2 2017
Pipeline by Bolder Biotechnology Inc H2 2017
Pipeline by Genzyme Corp H2 2017
Pipeline by Johnson & Johnson H2 2017
Pipeline by OncBioMune Pharmaceuticals Inc H2 2017
Pipeline by Pharmaxis Ltd H2 2017
Pipeline by Savara Inc H2 2017
Pipeline by Targovax ASA H2 2017
Pipeline by XL-protein GmbH H2 2017
Dormant Products H2 2017
Dormant Products H2 2017 (Contd..1) H2 2017
Discontinued Products H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881476/buy/3500
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)-Granulocyte macrophage colony stimulating factor receptor subunit alpha also known as CD116 is a receptor for granulocyte macrophage colony-stimulating factor. It is a member of the cytokine family of receptors. It plays an important role in controls the production differentiation and function of granulocytes and macrophages.
The report 'Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha-Pipeline Review H2 2017' outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development with respective active and dormant or discontinued projects. Currently The molecules developed by companies in Phase III Phase II Phase I and Preclinical stages are 2 4 1 and 3 respectively. Similarly the universities portfolio in Preclinical stages comprises 1 molecules respectively. Report covers products from therapy areas Oncology Respiratory Toxicology Central Nervous System Dermatology Gastrointestinal and Infectious Disease which include indications Prostate Cancer Colorectal Cancer Lung Disease Melanoma Radiation Toxicity (Radiation Sickness Acute Radiation Syndrome) Acute Respiratory Distress Syndrome Alzheimer's Disease Appendicitis Asthma Chemotherapy Induced Neutropenia Chronic Obstructive Pulmonary Disease (COPD) Crohn's Disease (Regional Enteritis) Lung Infections Lung Injury Malignant Pleural Mesothelioma Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Mild Cognitive Impairment Neurology Ovarian Cancer Parkinson's Disease Peritonitis Radiation Induced Myelosuppression Radiation Injury Respiratory Syncytial Virus (RSV) Infections Skin Ulcers and Wounds.
For more information about this report at http://www.reportsweb.com/granulocyte-macrophage-colony-stimulating-factor-receptor-subunit-alpha-pipeline-review-h2-2017
Report Scope
- The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
- The report reviews Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
- The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001881476/sample
Reasons to buy
- Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Company profiles
Aduro BioTech Inc
Bolder Biotechnology Inc
Genzyme Corp
Johnson & Johnson
OncBioMune Pharmaceuticals Inc
Pharmaxis Ltd
Savara Inc
Targovax ASA
XL-protein GmbH
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001881476/discount
List of Tables
Number of Products under Development by Stage of Development H2 2017
Number of Products under Development by Therapy Areas H2 2017
Number of Products under Development by Indications H2 2017
Number of Products under Development by Indications H2 2017 (Contd..1) H2 2017
Number of Products under Development by Companies H2 2017
Products under Development by Companies H2 2017
Products under Development by Companies H2 2017 (Contd..1) H2 2017
Number of Products under Investigation by Universities/Institutes H2 2017
Products under Investigation by Universities/Institutes H2 2017
Number of Products by Stage and Mechanism of Actions H2 2017
Number of Products by Stage and Route of Administration H2 2017
Number of Products by Stage and Molecule Type H2 2017
Pipeline by Aduro BioTech Inc H2 2017
Pipeline by Bolder Biotechnology Inc H2 2017
Pipeline by Genzyme Corp H2 2017
Pipeline by Johnson & Johnson H2 2017
Pipeline by OncBioMune Pharmaceuticals Inc H2 2017
Pipeline by Pharmaxis Ltd H2 2017
Pipeline by Savara Inc H2 2017
Pipeline by Targovax ASA H2 2017
Pipeline by XL-protein GmbH H2 2017
Dormant Products H2 2017
Dormant Products H2 2017 (Contd..1) H2 2017
Discontinued Products H2 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001881476/buy/3500
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results